EQ Inc

EQ Inc's capital structure is highly leveraged, with total liabilities of CAD 4.53 billion and total equity of CAD -1.46 billion, resulting in a negative debt-to-equity ratio of -0.52. Despite a negative equity position, the company maintains a net operating cash flow of CAD 1.05 billion, but its free cash flow is negative at CAD -791 million, indicating that capital expenditures are not being fully offset by operating cash flow. The current ratio of 0.47 suggests liquidity constraints, as current assets are significantly lower than current liabilities.

Profitability metrics reveal a challenging operating environment for EQ Inc. The company reported a net loss of CAD 880 million, with an operating loss of CAD 833 million, translating to a negative return on assets of -28.7%. While the return on equity is positive at 60.2%, this is largely due to the negative equity base, which inflates the ratio and does not reflect true operational performance.

Geographically, EQ Inc's revenue is concentrated in a single jurisdiction, as no segment or geographic breakdown is disclosed in the available data. This lack of diversification increases exposure to regional economic and regulatory risks, particularly in the advertising and marketing industry, which is sensitive to macroeconomic cycles and consumer spending trends.

Looking ahead, EQ Inc's growth trajectory is uncertain. The company's operating income and net income are both negative, and no specific revenue growth or decline percentages are provided in the outlook. However, the negative free cash flow and high leverage suggest that the company may need to either improve operational efficiency or secure additional financing to sustain operations.

The risk assessment highlights medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in meeting short-term obligations. While dilution risk is currently low, the company's negative equity and high leverage could necessitate future equity or debt financing, which may increase dilution pressure.

Recent filings and transcripts do not provide specific details on strategic initiatives or operational changes. However, the negative operating and net income, combined with the negative free cash flow, suggest that the company is under financial pressure and may need to implement cost-cutting measures or seek external financing to stabilize its position.

Analysts project 651.9% upside to a mean price target of $7.14, reflecting strong buy recommendations from eight analysts.

Operating and net margins exceed the 75th percentile of the pharmaceuticals and medical research cohort median benchmarks.

The company maintains a low leverage band with a debt-to-equity ratio of 0.34 and a current ratio of 3.93.

Dilution risk is assessed as low, suggesting limited immediate threat to shareholder equity value from share issuance.

Revenue declined at a 4.4% compound annual growth rate over four years, indicating persistent top-line contraction.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or debt servicing.

Cash conversion ranks in the bottom quartile of the cohort, highlighting inefficiencies in turning operations into cash.

Medium liquidity risk flags potential challenges in meeting short-term obligations despite a strong current ratio.

Revenue C$3.3M; Operating income -C$76.0k.

• ▍Revenue C$3.3M
• ▍Operating income -C$76.0k
• ▍Net margin -4.3%

Revenue C$2.5M; Operating income C$650.0k.

• ▍Revenue C$2.5M
• ▍Operating income C$650.0k
• ▍Net margin 24.4%

Revenue C$1.6M; Operating income -C$833.0k.

• ▍Revenue C$1.6M
• ▍Operating income -C$833.0k
• ▍Net margin -56.6%

Revenue C$9.8M, −1,1% YoY; Operating income +88,1% YoY.

• ▍Revenue C$9.8M, −1,1% YoY
• ▍Operating income +88,1% YoY
• ▍Net income +84,8% YoY
• ▍Free cash flow +85,5% YoY
• ▍Net margin -9.1%

Revenue C$10.0M, −9,2% YoY; Operating income +8,6% YoY.

• ▍Revenue C$10.0M, −9,2% YoY
• ▍Operating income +8,6% YoY
• ▍Net income +8,3% YoY
• ▍Free cash flow +11,9% YoY
• ▍Net margin -59.2%

Revenue C$11.0M, −9,2% YoY; Operating income −8,9% YoY.

• ▍Revenue C$11.0M, −9,2% YoY
• ▍Operating income −8,9% YoY
• ▍Net income −8,1% YoY
• ▍Free cash flow −3,4% YoY
• ▍Net margin -58.6%

Revenue C$12.1M; Operating income -C$5.9M.

• ▍Revenue C$12.1M
• ▍Operating income -C$5.9M
• ▍Net margin -49.3%